These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15381022)

  • 1. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease.
    Fern-Pollak L; Whone AL; Brooks DJ; Mehta MA
    Neuropsychologia; 2004; 42(14):1917-26. PubMed ID: 15381022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease.
    Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
    J Neurophysiol; 2010 Feb; 103(2):942-9. PubMed ID: 20018839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
    Tomer R; Aharon-Peretz J; Tsitrinbaum Z
    Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor procedural learning in Parkinson's disease.
    Muslimovic D; Post B; Speelman JD; Schmand B
    Brain; 2007 Nov; 130(Pt 11):2887-97. PubMed ID: 17855374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
    Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
    Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease.
    Scholtissen B; Verhey FR; Adam JJ; Prickaerts J; Leentjens AF
    J Neurol Sci; 2006 Oct; 248(1-2):259-65. PubMed ID: 16756999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
    Lange KW; Paul GM; Naumann M; Gsell W
    J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
    Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M
    Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic medication boosts action-effect binding in Parkinson's disease.
    Moore JW; Schneider SA; Schwingenschuh P; Moretto G; Bhatia KP; Haggard P
    Neuropsychologia; 2010 Mar; 48(4):1125-32. PubMed ID: 20018200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteers.
    Mehta MA; Hinton EC; Montgomery AJ; Bantick RA; Grasby PM
    J Psychopharmacol; 2005 Jan; 19(1):29-38. PubMed ID: 15671126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers.
    Mehta MA; Swainson R; Ogilvie AD; Sahakian J; Robbins TW
    Psychopharmacology (Berl); 2001 Dec; 159(1):10-20. PubMed ID: 11797064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal contribution to cognition: working memory and executive function in Parkinson's disease before and after unilateral posteroventral pallidotomy.
    Jahanshahi M; Rowe J; Saleem T; Brown RG; Limousin-Dowsey P; Rothwell JC; Thomas DG; Quinn NP
    J Cogn Neurosci; 2002 Feb; 14(2):298-310. PubMed ID: 11970793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: does the therapy-dose matter?
    Torta DM; Castelli L; Zibetti M; Lopiano L; Geminiani G
    Brain Cogn; 2009 Nov; 71(2):84-91. PubMed ID: 19442427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism.
    Moustafa AA; Sherman SJ; Frank MJ
    Neuropsychologia; 2008 Nov; 46(13):3144-56. PubMed ID: 18687347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of Parkinson's disease on sequence learning: perceptual pattern learning and executive function.
    Price A; Shin JC
    Brain Cogn; 2009 Mar; 69(2):252-61. PubMed ID: 18786754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
    Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
    Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
    Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF
    Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.